---
title: "HSBC Research: Market worries that AK112 is less effective for Western patients than for Asian patients, slightly lowering AKESO's target price to 205 yuan"
description: "HSBC's research report pointed out that the efficacy of AK112 from AKESO is lower in Western patients compared to Asian patients, leading to market concerns. The bank has lowered its peak sales foreca"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/256476688.md"
published_at: "2025-09-09T02:26:37.000Z"
---

# HSBC Research: Market worries that AK112 is less effective for Western patients than for Asian patients, slightly lowering AKESO's target price to 205 yuan

> HSBC's research report pointed out that the efficacy of AK112 from AKESO is lower in Western patients compared to Asian patients, leading to market concerns. The bank has lowered its peak sales forecast for AK112 and slightly reduced the target price from 208 yuan to 205 yuan, maintaining a "Buy" rating. Although the stock price opened nearly 6% lower this morning, it is expected that the compound annual growth rate of sales from 2025 to 2027 will reach 50%

HSBC Global Research report indicates that Akeso (09926.HK) partner Summit Therapeutics recently updated the global Phase III HARMONi study data comparing AK112 combined chemotherapy with platinum-based doublet chemotherapy. The results are generally consistent with earlier data, but the market is concerned that AK112 may be less effective in Western patients compared to Asian patients. Additionally, the differences between the global HARMONi trial and the China-exclusive HARMONi-A trial data may impact its overseas commercial prospects.

As a result, the bank has lowered its peak sales forecast for EGFR mutation non-small cell lung cancer (NSCLC) to reflect the weakening of its competitive advantage. At the same time, the bank believes that the current valuation of the shares remains attractive, expecting a compound annual growth rate of 50% in sales from 2025 to 2027; it maintains a "Buy" rating on Akeso, with a target price slightly reduced from 208 yuan to 205 yuan.

Akeso opened nearly 6% lower this morning, hitting a low of 129.6 yuan during the session, down 9.1% at one point, and is currently trading at 139.7 yuan, down nearly 2%, with a transaction volume of 1.663 billion yuan

### Related Stocks

- [09926.HK - AKESO](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Akeso's Ivonescimab Shows Significant Survival Benefits in HARMONi-A Phase III NSCLC Trial | Akeso Inc. announced a significant label update for its bispecific antibody, ivonescimab, after approval by China's Nati | [Link](https://longbridge.com/en/news/271728127.md) |
| The Bull Case For Akeso (SEHK:9926) Could Change Following FDA Clearance Of Global Gastric Cancer Trial | Akeso has received FDA approval for a global Phase III trial of cadonilimab in advanced HER2-negative gastric cancer, ma | [Link](https://longbridge.com/en/news/269971630.md) |
| Akeso, Inc. Announces Presentation of Real-World Study At the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium | Akeso, Inc. announced a real-world study presentation at the 2026 ASCO GI Symposium, comparing cadonilimab plus chemothe | [Link](https://longbridge.com/en/news/272499977.md) |
| Akeso's Ivonescimab Shows Strong Phase 3 Results in Lung Cancer Trial | Akeso's Ivonescimab Shows Strong Phase 3 Results in Lung Cancer Trial | [Link](https://longbridge.com/en/news/261967652.md) |
| Akeso Reports Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer Study | Akeso Inc. reported that cadonilimab plus chemotherapy outperformed PD-1 inhibitors in a study for first-line treatment  | [Link](https://longbridge.com/en/news/272494568.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.